Portfoliotracker

Immatics N.V.

IMTX · NASDAQCM · Healthcare Biotechnology 22/100 E

6,170 $
▼ −0,220 (−3,44 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:16
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score22 / 100 Market cap973 mil. $ P/E– Forward P/E-3,1 P/S22,4 P/B2,0 EV/EBITDA-2,9 Dividend yield– FCF yield– EPS-1,92 $ Net margin0,0 % Return on equity-54,3 % Beta– Debt / equity0,03
52-week range 6,07 to 12,41
3-month average volume0,9 M

We do not have financial statements yet

The company reports in EUR, while the price is quoted in USD. We do not convert statements between currencies yet, because the multiples (P/E, P/S and others) would come out wrong, so we do not show them here. You can see the price and its history above.

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Employees
589
Country
Germany
Data since
12. 12. 2018

Explore further

Similar companies IMCRBCYCIDYAREPLNRIX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account